What happened with CARL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Carlsmed helps surgeons plan spinal fusion procedures and supplies implants shaped for each patient. Its aprevo Technology Platform uses diagnostic images and AI-enabled software to create a surgical plan and design an implant that fits the patient’s anatomy. After the surgeon approves both, contract manufacturers 3D-print the titanium implant and supply a sterile surgical kit with single-use instruments. The platform is commercially available in the United States for lumbar and cervical fusion procedures.
Hospitals are the main purchasers, alongside ambulatory surgical centers. Carlsmed invoices these facilities for its products rather than billing insurers; the facilities and surgeons seek reimbursement separately. Product sales drive revenue, so the business depends on attracting surgeons and getting existing users to choose aprevo for more procedures. Insurance coverage and adequate reimbursement influence whether facilities adopt the products.
Carlsmed relies on a limited number of outside manufacturers for all implant production, making delivery in time for scheduled surgeries essential. Its commercial devices have FDA clearance, and the company may not promote them for uses outside their authorized indications.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Alphatec competes with Carlsmed for surgeons’ choice of spinal implants used in fusion procedures at healthcare facilities. Watch adoption of Alphatec’s approach-specific procedures: Carlsmed’s revenue growth also depends on adding surgeon users and getting existing users to perform more cases.
Globus Medical’s off-the-shelf spinal implants compete with the patient-specific implants Carlsmed sells to hospitals and ambulatory surgical centers for spine fusion. Its spinal implant products are the relevant competition to watch, rather than its broader imaging, navigation and surgical robotics offerings.
Orthofix competes with Carlsmed for surgeon adoption of implants used in spinal fusion at healthcare facilities. Its Global Spine sales are the relevant line to watch: that segment accounted for 84% of total net sales in 2025, including product sales and marketing service fees.
Medtronic’s off-the-shelf spinal implants compete with the patient-specific interbody implants Carlsmed sells to hospitals and ambulatory surgical centers. Spine is only part of Medtronic’s business, so its spinal implant news is more relevant to this rivalry than developments in its diabetes products.
Xtant Medical competes with Carlsmed in spinal fusion, selling spinal implant fixation systems through surgeon-facing channels to hospitals. Watch its spinal implant business and sales-agent reach, rather than its biologics used outside spine surgery; Carlsmed also relies on agents to support surgeons and cover procedures.
Johnson & Johnson’s off-the-shelf spinal implants compete with the personalized implants Carlsmed sells to hospitals and ambulatory surgical centers. This rivalry is only a small part of Johnson & Johnson’s diversified business, so focus on spinal implant developments rather than its prescription medicine sales.
SI-BONE and Carlsmed both serve spinal fusion procedures, but supply different implants: SI-BONE provides pelvic fixation products, while Carlsmed sells interbody implants to hospitals and ambulatory surgical centers. Watch adoption of SI-BONE’s pelvic fixation products in spine fusion, rather than treating all of its sacroiliac joint and pelvic trauma business as a signal for Carlsmed.
Orthofix Medical Inc. earningsOFIX
Orthofix’s report will show sales in its Global Spine business, a direct read on surgeon adoption of spinal-fusion products that compete with Carlsmed’s.
Focus on Global Spine sales, not Orthofix’s total sales. Stronger sales would show continued demand for spinal-fusion products and active competition for surgeons’ adoption of aprevo; weaker sales would suggest softer market demand or adoption, though Orthofix alone cannot establish how Carlsmed’s own sales changed.
Carlsmed, Inc. earningsThis company
Carlsmed sells personalized implants for spine-fusion surgery to hospitals, and this report will show whether more surgeons and hospitals are bringing more procedures without eroding manufacturing economics.
Read procedure volume, revenue per procedure and gross margin together. More procedures with revenue per procedure broadly steady and margin holding would show surgeon adoption is expanding while manufacturing efficiency supports scale; slower volume growth or a falling margin would point to adoption or manufacturing cost limiting the business.
Xtant Medical Holdings, Inc. earningsXTNT
Xtant Medical’s spinal-implant sales will show whether its surgeon-facing channels are winning hospital fusion cases, a competitive test for Carlsmed’s own surgeon outreach.
Watch Xtant’s spinal-implant business, not its biologics sales. Stronger implant sales would show that surgeon-facing channels are translating into hospital procedure demand, making competition for Carlsmed’s surgeon adoption more forceful; weaker sales would indicate less traction for this channel, not that Carlsmed has won more cases.
